» Articles » PMID: 17331125

Treatment of Staphylococcal Prosthetic Joint Infections with Debridement, Prosthesis Retention and Oral Rifampicin and Fusidic Acid

Overview
Publisher Elsevier
Date 2007 Mar 3
PMID 17331125
Citations 56
Authors
Affiliations
Soon will be listed here.
Abstract

There is growing evidence of the efficacy of treating early staphylococcal infections of prosthetic joints with surgical debridement and prosthesis retention, combined with oral antibiotic regimens that include rifampicin in combination with a fluoroquinolone. With rising rates of fluoroquinolone-resistant staphylococci, evidence concerning the efficacy of alternative combinations of antibiotics is required. Twenty patients with staphylococcal prosthetic joint infections who had been treated with surgical debridement and prosthesis retention, and a combination of rifampicin and fusidic acid were analysed. The mean duration of symptoms before initial debridement was 16 (range 2-75) days. The median time of follow-up was 32 (range 6-76) months. Treatment failure occurred in two patients. The cumulative risk of treatment failure after 1 year was 11.76% (95% CI 3.08-39.40%). Two patients had their treatment changed because of nausea. Ten of 11 patients with infections involving methicillin-resistant Staphylococcus aureus had successful outcomes. Debridement without prosthesis removal, in combination with rifampicin and fusidic acid treatment, was effective and should be considered for patients with early staphylococcal prosthetic joint infections, including those with infections involving fluoroquinolone-resistant organisms.

Citing Articles

Current Strategies in Developing Antibacterial Surfaces for Joint Arthroplasty Implant Applications.

Cardoso G, Correa D, Fosca M, Pometun E, Antoniac I, Grandini C Materials (Basel). 2025; 18(1.

PMID: 39795818 PMC: 11722469. DOI: 10.3390/ma18010173.


The Role of Rifampin in Prosthetic Joint Infections: Efficacy, Challenges, and Clinical Evidence.

Pupaibool J Antibiotics (Basel). 2025; 13(12.

PMID: 39766613 PMC: 11727642. DOI: 10.3390/antibiotics13121223.


Identification of human pregnane X receptor antagonists utilizing a high-throughput screening platform.

Lynch C, Margolis R, Niebler J, Travers J, Sakamuru S, Zhao T Front Pharmacol. 2024; 15:1448744.

PMID: 39508053 PMC: 11537999. DOI: 10.3389/fphar.2024.1448744.


Modular component exchange has no advantage in Debridement, Antibiotics and Implant Retention (DAIR) for early onset hip and knee prosthetic joint infection.

Gavaskar A, Tummala N, Srinivasan P, Ayyadurai P, Ganesh D, Reddy R Arch Orthop Trauma Surg. 2024; 144(12):5261-5266.

PMID: 39316104 DOI: 10.1007/s00402-024-05546-5.


Antibiotics with antibiofilm activity - rifampicin and beyond.

Ferreira L, Pos E, Nogueira D, Ferreira F, Sousa R, Abreu M Front Microbiol. 2024; 15:1435720.

PMID: 39268543 PMC: 11391936. DOI: 10.3389/fmicb.2024.1435720.